30 January 2025
Physiomics plc
("Physiomics" or the "Company")
Publication of Peer Reviewed
Article
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce the
joint online publication in collaboration with Merck KGaA entitled
'Semi-mechanistic efficacy model for PARP + ATR inhibitors -
application to rucaparib and talazoparib in combination with
gartisertib in breast cancer PDXs' in the British Journal of
Cancer.
The full article can be accessed via
the following link: https://www.nature.com/articles/s41416-024-02935-w
The development of novel effective
oncology therapies is very challenging, not only from a cost
perspective, but due to biological factors such as the emergence of
tumour resistance and natural patient-to-patient variations that
influence treatment outcomes. Combination therapies, such as those
described within the paper, can offer a route to overcoming some of
these biological factors and offer more successful
treatments.
In contrast to developing
monotherapies (single drug therapies), the development of
combination therapies creates additional complexity to the
development process as a larger number of possible experimental
permutations need to be explored. If all these permutations were to
be explored within preclinical or clinical settings, the additional
cost and time required would become prohibitive. Physiomics
addresses this challenge by offering prediction services that can
be used to understand how these novel therapeutics might perform in
the clinic, enabling a way to focus in on the most effective
experimental permutations to explore, thus accelerating and
derisking the drug development process.
In this publication, a mathematical
model was developed to explore these different experimental
permutations (doses and schedules) for combination therapies. Using
Physiomics' proprietary 'Virtual Tumour' platform, the model
provided a single, readily interpretable readout of tumour growth
inhibition (TGI). It was also able to assess the variation in
treatment response of novel drug combinations at various doses, and
therefore could be used to inform clinical trial protocol
design.
This joint publication with
Physiomics' long-standing client, Merck KGaA, demonstrates the
impact of the Company's Virtual Tumour platform in supporting the
development of novel Oncology Therapies. Physiomics provides
expertise in using modelling and simulation approaches to
accelerate the development of innovative therapies across a range
of therapeutic areas and across the entire drug development
pathway, including early discovery and
development.
Dr
Peter Sargent, CEO, commented:
"We
are thrilled to be able to announce this peer-reviewed publication.
This is the second publication we've announced this month,
highlighting the utility and benefit of our Virtual Tumour Model in
supporting oncology drug development. The work described within the
publication is testament to our continued relationship with Merck
KGaA, a relationship established over 12 years ago and spanning
over 30 contracts."
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0) 1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Limited (NOMAD)
James Dance & James Bellman
+44 (0) 20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
